Clinical Trial Search

Primary: Percentage of Participants With HBV DNA < 400 Copies/mL at Week 96 — 89.4; 86.3 percentage of participants — p=0.43

Primary: Change From Baseline to the End of the Double- Blind Treatment Period (Week 12) in Polysomnography (PSG) Defined Latency to Persistent Sleep (LPS). — -18.33; -23.45…

Primary: Percentage of Participants With New Vertebral Fractures Through Month 36 — 1.98; 2.14; 1.84; 3.13 Percentage of participants — p=0.22

Primary: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) — 24.4; 18.0; -1.4 Liters per minute

Primary: Nail Bed Clearing

Primary: Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 4 — 64; 60; 5; 2 participants

Primary: Median of the Individual Subject's Rate of Adverse Events (AEs) Per Infusion — 0.167; 0.125; 0; 0 AEs per infusion

Primary: Proportion of Children of Diarrhea Episodes — 19.1; 14.7 percentage of participants

Primary: Median Time to Achieve Target SBP Range (≤160 mmHg to ≥140 mmHg) Within 30 Minutes of Initiation of Clevidipine — 5.5 minutes

Primary: Responder Rate — 60.7; 63.6 percentage of responders

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) — -0.89; -0.42; -0.70; -0.29 percentage of glycosylated hemoglobin

Primary: %Excess Weight Loss 4-6 Weeks After Surgery (Large and Small Bands) — 15.63; 20.8 %EWL

Primary: Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c) (Grouped Analysis) — -0.89; -1.43; -1.42 percentage of glycosylated hemoglobin — p=<0.001

Primary: Hearing Improvement — 30.7; 28.7 dB

Primary: Number of Subjects Reporting at Least One Confirmed Occurrence of Influenza A or B. — 58; 128 subjects